Dr. Robert Hancock reports

ASEP MEDICAL HOLDINGS INC. ASEP MEDICAL RAISES 5 MILLION RMB THROUGH THE SALE OF A 10% STAKE IN CHINESE JOINT VENTURE

ASEP Medical Holdings Inc.'s subsidiary, Sepset Biosciences Inc., has raised five million renminbi (approximately $964,000) through the sale of a 10-per-cent equity interest in its Chinese joint venture, Hunan Sanway SepSmart Ltd., to Sansure Biotech Inc. The transaction was completed on Sept. 4, 2025.

Following this transaction, Sepset retains a 15-per-cent ownership stake in SepSmart. This strategic investment by Sansure reflects a decisive vote of confidence in Sepset's sepsis diagnostic technology and provides additional capital to accelerate its development and commercialization in China and globally. SepSmart was established as a joint venture between Sepset Biosciences and Sansure Biotech to advance Sepset's rapid sepsis diagnostic test, known as SepsetER, in the Chinese market.

Dr. Robert E.W. Hancock, ASEP Medical's chair, chief executive officer and inventor of the Sepset technology, stated: "We are excited by Sansure's ongoing support of our vision. This investment provides essential resources to advance our Sepset diagnostic technology and will help push our efforts forward in the global fight against sepsis."

The $964,000 capital injection will enable Sepset to accelerate its continuing development programs and bring the SepsetER test closer to widespread clinical use, supporting ASEP Medical's mission to combat sepsis worldwide.

The company is also announcing the termination of its SafeCoat Medical Inc. licence agreement with the University of British Columbia (UBC), effective Sept. 4, 2025. The decision reflects ASEP Medical's disciplined focus on its core businesses, Sepset Biosciences and ABT Innovations, and is intended to streamline operations and dedicate financial resources where the company sees the most immediate strategic opportunity. Following the termination, the entity associated with the licence will be inactive. The company's priority remains advancing its Sepset sepsis diagnostic platform and ABT's anti-biofilm technologies to drive clinical impact and long-term value.

About ASEP Medical Holdings Inc.

ASEP Medical is a standout biotechnology research and development company based in Victoria, B.C., Canada. The company possesses a valuable portfolio of global patents for innovative diagnostic and therapeutic medical technologies. These technologies were developed over the past decade at the University of British Columbia under the guidance of Dr. Hancock, one of the world's foremost microbiologists and the CEO of ASEP. ASEP holds a controlling interest in two private subsidiary companies -- Sepset Biosciences (ASEP's leading product, a sepsis diagnostic technology) and ABT Innovations (specializing in anti-biofilm technology). As the company's patented innovations cater to unmet medical needs, it offers a unique investment opportunity for retail and institutional investors. It is also an attractive buyout target for a major global pharmaceutical operator.

We seek Safe Harbor.